The Long Pentraxin Ptx3 Is Synthesized in IgA Glomerulonephritis and Activates Mesangial Cells 1

The long pentraxin PTX3 has been recently involved in amplification of the inflammatory reactions and regulation of innate immunity. In the present study we evaluated the expression and role of PTX3 in glomerular inflammation. PTX3 expression was investigated in the IgA, type I membranoproliferative, and diffuse proliferative lupus glomerulonephritis, which are characterized by inflammatory and proliferative lesions mainly driven by resident mesangial cells, and in the membranous glomerulonephritis and the focal segmental glomerular sclerosis, where signs of glomerular inflammation are usually absent. We found an intense staining for PTX3 in the expanded mesangial areas of renal biopsies obtained from patients with IgA glomerulonephritis. The pattern of staining was on glomerular mesangial and endothelial cells. Scattered PTX3-positive cells were also detected in glomeruli of type I membranoproliferative glomerulonephritis. The concomitant expression of CD14 suggests an inflammatory origin of these cells. Normal renal tissue and biopsies from patients with the other glomerular nephropathies studied were mainly negative for PTX3 expression in glomeruli. However, PTX3-positive cells were detected in the interstitium of nephropathies showing inflammatory interstitial injury. In vitro, cultured human mesangial cells synthesized PTX3 when stimulated with TNF-α and IgA and exhibited specific binding for recombinant PTX3. Moreover, stimulation with exogenous PTX3 promoted mesangial cell contraction and synthesis of the proinflammatory lipid mediator platelet-activating factor. In conclusion, we provide the first evidence that mesangial cells may both produce and be a target for PTX3. The detection of this long pentraxin in the renal tissue of patients with glomerulonephritis suggests its potential role in the modulation of glomerular and tubular injury.

[1]  M. Byrne,et al.  Knockout of pentraxin 3, a downstream target of growth differentiation factor-9, causes female subfertility. , 2002, Molecular endocrinology.

[2]  Mauro M Teixeira,et al.  Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. , 2002, The American journal of pathology.

[3]  C. Garlanda,et al.  Production of the Long Pentraxin PTX3 in Advanced Atherosclerotic Plaques , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[4]  A. Mantovani,et al.  Long Pentraxin PTX3 Upregulates Tissue Factor Expression in Human Endothelial Cells: A Novel Link Between Vascular Inflammation and Clotting Activation , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[5]  A. Mantovani,et al.  PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. , 2001, Arthritis and rheumatism.

[6]  V. Torri,et al.  Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients , 2001, Critical care medicine.

[7]  L. Reis,et al.  TSG‐14 transgenic mice have improved survival to endotoxemia and to CLP‐induced sepsis , 2001, Journal of leukocyte biology.

[8]  C. Garlanda,et al.  The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. , 2000, Blood.

[9]  M. Daha Mechanisms of mesangial injury in glomerular diseases. , 2000, Journal of nephrology.

[10]  G Olivetti,et al.  PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. , 2000, Circulation.

[11]  A. Mantovani,et al.  Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA) , 2000, Clinical and experimental immunology.

[12]  T. D. Du Clos Function of C-reactive protein , 2000, Annals of medicine.

[13]  M. Haubitz,et al.  Activation of the acute phase response and complement C3 in patients with IgA nephropathy. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  N. Yoshikawa,et al.  Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  R. Foà,et al.  Interleukin-12 is synthesized by mesangial cells and stimulates platelet-activating factor synthesis, cytoskeletal reorganization, and cell shape change. , 1999, The American journal of pathology.

[16]  Francesco Tedesco,et al.  Multimer Formation and Ligand Recognition by the Long Pentraxin PTX3 , 1997, The Journal of Biological Chemistry.

[17]  P. Kimmel Role of mesangium in microcirculatory control. , 1997, Blood purification.

[18]  T. Blundell,et al.  Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. , 1996, Blood.

[19]  T. Lint,et al.  Structure and function of the pentraxins. , 1995, Current opinion in immunology.

[20]  J. Robotham,et al.  The acute-phase response. , 1995, New horizons.

[21]  A. Mantovani,et al.  Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. , 1994, Blood.

[22]  Ann Chen,et al.  Pathogenesis of IgA nephropathy: In vitro activation of human mesangial cells by IgA immune complex leads to cytokine secretion , 1994, The Journal of pathology.

[23]  G. Camussi Interactive effects of tumor necrosis factor and platelet-activating factor in the pathogenesis of glomerular injury. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[24]  L. McManus,et al.  PAF molecular heterogeneity: pathobiological implications. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[25]  J. Vilček,et al.  TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. , 1993, Journal of immunology.

[26]  M. Rocchi,et al.  Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. , 1992, The Journal of biological chemistry.

[27]  J. Neugarten,et al.  Protective effects of specific platelet-activating factor receptor antagonists in experimental glomerulonephritis. , 1991, The Journal of pharmacology and experimental therapeutics.

[28]  E. Baldi,et al.  Platelet activating factor receptor blockade ameliorates murine systemic lupus erythematosus. , 1990, Kidney international.

[29]  G. Camussi,et al.  Tumor necrosis factor induces contraction of mesangial cells and alters their cytoskeletons. , 1990, Kidney international.

[30]  M. Dunn,et al.  Physiology of the mesangial cell. , 1989, Physiological reviews.

[31]  G. Camussi,et al.  Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor , 1987, The Journal of experimental medicine.

[32]  G. Camussi,et al.  Receptor antagonist of platelet activating factor inhibits inflammatory injury induced by in situ formation of immune complexes in renal glomeruli and in the skin. , 1987, The Journal of laboratory and clinical medicine.

[33]  Striker Ge,et al.  Glomerular cell culture. , 1985 .

[34]  G. Striker,et al.  Glomerular cell culture. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[35]  L. Baud,et al.  Effect of platelet-activating factor and serum-treated zymosan on prostaglandin E2 synthesis, arachidonic acid release, and contraction of cultured rat mesangial cells. , 1984, The Journal of clinical investigation.

[36]  H. Gewurz,et al.  Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[37]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.